Epicardial Cardiac Fat-CT (EPIC-CT)
A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 136 participants.
Also called NCT07297589
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 136 participants
- Sponsor
- Instituto Mexicano del Seguro Social
- Registry
-
NCT07297589
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Mexico
- Registry status
- Recruiting
Technical summary
Registry record NCT07297589. Randomized; single masking; primary purpose treatment. Start 2025-12-30 (actual); primary completion 2027-01 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Epicardial Cardiac Fat-CT (EPIC-CT)
- Acronym
- EPIC-CT
- Condition
- STEMI - ST Elevation Myocardial Infarction
- Condition
- Epicardial Fat
- Intervention (Drug)
- Dapagliflozin 10 MG Oral Tablet
- Intervention (Drug)
- Semaglutide (Rybelsus®)
- Lead sponsor
- Instituto Mexicano del Seguro Social
Record details
- Record id
cardio:ct-nct07297589- Content hash
038f3036cfa866ce813f2cc2aef53ed0f4d6cdcb38831403918473b102273c95